| Porphyrin-polyamine conjugates for cancer therapy -> Monitor Keywords |
|
|
  Porphyrin-polyamine conjugates for cancer therapyUSPTO Application #: 20060276444Title: Porphyrin-polyamine conjugates for cancer therapy Abstract: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed. (end of abstract) Agent: Morrison & Foerster LLP - Palo Alto, CA, US Inventors: Benjamin Frydman, Linda Clifford, Aldonia L. Valasinas, Venodhar K. Reddy, Hirak S. Basu, Aparajita Sarkar, Subhra Bhattacharya, Yu Wang, Laurence J. Marton, Andrei V. Blokhin Related Keywords: anticancer, cancer, cancer therapy, conjugate USPTO Applicaton #: 20060276444 - Class: 514185000 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai, Heavy Metal Containing (including Salts), Polycyclo Ring System The Patent Description & Claims data below is from USPTO Patent Application 20060276444. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority benefit of U.S. Provisional Patent Application No. 60/392,171, filed Jun. 26, 2002. The content of that application is hereby incorporated by reference herein in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] Not applicable. REFERENCE TO AN APPENDIX [0003] Not applicable. TECHNICAL FIELD [0004] This invention relates to porphyrin-polyamine conjugate compounds used for treatment of cancer and other diseases. BACKGROUND OF THE INVENTION [0005] Cancer is the third most common cause of death in the world according to the World Health Organization, after heart disease and infectious disease. Cancer is the second most common cause of death (after heart disease) in the developed world. Accordingly, discovery of new and effective treatments for cancer is a high priority for health care researchers. [0006] Cancer is often treated by using chemotherapy to selectively kill or hinder the growth of cancer cells, while having a less deleterious effect on normal cells. Chemotherapeutic agents often kill rapidly dividing cells, such as cancer cells; non-malignant cells which are dividing less rapidly are affected to a lesser degree. Other agents, such as antibodies attached to toxic agents, have been evaluated for use against cancers. These agents target the cancer cells by making use of a characteristic specific to the cancer, for example, higher-than-normal rates of cell division, or unique antigens expressed on the cancer cell surface. [0007] As toxic agents specifically targeted against cancer cells can enhance therapeutic efficacy, reduce undesirable side effects, or both, many efforts have been made to achieve selective localization of well-defined chemical materials in malignant tumors. A significant advance in the field occurred with the introduction of tetraphenylporphine sulfonates (TPPS), which are non-naturally occurring porphyrins (Winkelman J. (1962) Cancer Res. 22:589). A hematoporphyrin derivative (HPD) was also found to localize in tumors (Lipson R L, Baldes, E J, & Gray M S (1967) Cancer 20: 2255). HPD is a complex mixture of porphyrins currently used as a sensitizer derivative that concentrates in tumor cells and destroys them after the tumor is irradiated with light or a laser beam (Dougherty T J, (1987) Photochem. Photobiol. 45:879). A wide variety of porphyrins and porphyrin analogues have been found to be selectively taken up by tumors, such as the naturally occurring porphyrins; for example, the octacarboxylic uroporphyrins, the tetracarboxylic coproporphyrins, and the dicarboxylic protoporphyrin. Synthetic porphyrins are also selectively taken up by tumors; among them are the meso-tetraphenyl porphyrins and the different porphyrin sulfonates TPPS.sub.4, TPPS.sub.3, TPPS.sub.2a and TPPS.sub.1, which are listed in order of decreasing number of sulfonic acid substituents and decreasing hydrophilicity. Many factors determine the uptake and concentration of porphyrins in the tumors; one important factor is the structure (hydrophobicity, size, polarity) of the drug; another important factor is the formulation in which it is delivered (Sternberg E and Dolphin D (1996) Current Med Chemistry 3, 239). The mechanism(s) of porphyrin localization in tumors is still not entirely clear; the more hydrophobic porphyrins are preferentially incorporated in the lipid core of lipoproteins. Tightly aggregated porphyrins circulate as unbound pseudomicellar structures which can be entrapped in the interstitial regions of the tumor, can be localized in macrophages, or can enter neoplastic cells via pinocytotic processes. Low density lipoproteins (LDL), which are endocytosed by neoplastic cells through a specific receptor-mediated pathway, display the most selective release of porphyrins into the tumors (Jori G (1989) Photosensitizing Compounds, Ciba Foundation Symp 146, pp 78-94). [0008] The present invention describes the synthesis and cytotoxic actions of porphyrin-polyamine conjugates. They are taken up by the tumor cells due to their porphyrin moiety, while the polyamine moiety provides the cytotoxic effects (see International Patent Application Nos. WO 00/66587 and WO 02/10142, and U.S. Pat. Nos. 6,392,098, 5,889,061, and 5,677,350). SUMMARY OF THE INVENTION [0009] The invention provides porphyrin-polyamine conjugate compounds and compositions comprising such compounds. [0010] In one embodiment, the invention embraces a composition comprising a compound according to the formula [0011] wherein at least one of J.sub.1, J.sub.2, J.sub.3, J.sub.4, J.sub.5, J.sub.6, J.sub.7 and J.sub.8 is independently M, where M is selected from the group consisting of --(B-A-B).sub.x-G-(B-A-B).sub.m--(N(P)--B-A-B).sub.n--K [0012] wherein each A is independently selected from the group consisting of: a nonentity, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, C.sub.3-C.sub.12 cycloalkyl, C.sub.3-C.sub.8 cycloaryl, C.sub.3-C.sub.12 cycloalkenyl, C.sub.3-C.sub.12 cycloalkynyl, C.sub.1-C.sub.12 alkanol, C.sub.3-C.sub.12 cycloalkanol, and C.sub.3-C.sub.8 hydroxyaryl; [0013] each B is independently selected from the group consisting of: a nonentity, C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, C.sub.3-C.sub.12 cycloalkyl, C.sub.3-C.sub.8 cycloaryl, C.sub.3-C.sub.12 cycloalkenyl, C.sub.3-C.sub.12 cycloalkynyl, C.sub.1-C.sub.12 alkanol, C.sub.3-C.sub.12 cycloalkanol, and C.sub.3-C.sub.8 hydroxyaryl; [0014] and with the proviso that each --B-A-B-- unit contain at least one carbon atom; [0015] wherein G is independently selected from the group consisting of --N(P)--, --(C.dbd.O)--N(P)--, --N(P)--(C.dbd.O)--, and a nonentity; [0016] x is independently 0 or 1; [0017] m is independently 0 or 1; [0018] n is independently an integer from 0 to 20; Continue reading... Full patent description for Porphyrin-polyamine conjugates for cancer therapy Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Porphyrin-polyamine conjugates for cancer therapy patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Porphyrin-polyamine conjugates for cancer therapy or other areas of interest. ### Previous Patent Application: Methods of female sexual enhancement Next Patent Application: Bicyclic 6-alkylidene-penems as class-d beta-lactamases inhibitors Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Porphyrin-polyamine conjugates for cancer therapy patent info. IP-related news and info Results in 12.02015 seconds Other interesting Feshpatents.com categories: Electronics: Semiconductor , Audio , Illumination , Connectors , Crypto , |
||
